{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:38:35Z","timestamp":1777937915418,"version":"3.51.4"},"reference-count":31,"publisher":"Japanese Society of Toxicology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2131\/jts.51.321","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:16:13Z","timestamp":1777587373000},"page":"321-330","source":"Crossref","is-referenced-by-count":0,"title":["Ordinal association between cytochrome P450 inhibition and hepatotoxicity severity in rats"],"prefix":"10.2131","volume":"51","author":[{"given":"Nana","family":"Uchida","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Toxicology, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minami","family":"Shibata","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Toxicology, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ooka","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Toxicology, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka"},{"name":"Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Shizu","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Toxicology, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka"},{"name":"Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka"},{"name":"Research Institute of Science for Safety and Sustainability, National Institute of Advanced Industrial Science and Technology (AIST)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Yoshinari","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Toxicology, Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka"},{"name":"Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Allison, R., Guraka, A., Shawa, I.T., Tripathi, G., Moritz, W. and Kermanizadeh, A. (2023): Drug induced liver injury - a 2023 update. J. Toxicol. Environ. Health B Crit. Rev., <b>26<\/b>, 442-467.","DOI":"10.1080\/10937404.2023.2261848"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Ambe, K., Nakamori, M., Tohno, R., Suzuki, K., Sasaki, T., Tohkin, M. and Yoshinari, K. (2024): Machine Learning-Based <i>In Silico<\/i> Prediction of the Inhibitory Activity of Chemical Substances Against Rat and Human Cytochrome P450s. Chem. Res. Toxicol., <b>37<\/b>, 1843-1850.","DOI":"10.1021\/acs.chemrestox.4c00168"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bergander, L., Wincent, E., Rannug, A., Foroozesh, M., Alworth, W. and Rannug, U. (2004): Metabolic fate of the Ah receptor ligand 6-formylindolo[3,2-<i>b<\/i>]carbazole. Chem. Biol. Interact., <b>149<\/b>, 151-164.","DOI":"10.1016\/j.cbi.2004.08.005"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Cai, X., Young, G.M. and Xie, W. (2021): The xenobiotic receptors PXR and CAR in liver physiology, an update. Biochim. Biophys. Acta Mol. Basis Dis., <b>1867<\/b>, 166101.","DOI":"10.1016\/j.bbadis.2021.166101"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Feng, S. and He, X. (2013): Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity. Curr. Drug Metab., <b>14<\/b>, 921-945.","DOI":"10.2174\/138920021131400114"},{"key":"6","unstructured":"Food and Drug Administration. (2020a): In Vitro Drug Interaction Studies -Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. (Services, U.S.D.o.H.a.H., ed.), U.S.A."},{"key":"7","unstructured":"Food and Drug Administration. (2020b): Safety Testing of Drug Metabolites Guidance for Industry. (Services, U.S.D.o.H.a.H., ed.), Silver Spring, MD: Center for Drug Evaluation and Research."},{"key":"8","doi-asserted-by":"crossref","unstructured":"Floreani, M., Gabbia, D., Barbierato, M.D., Martin, S. and Palatini, P. (2012): Differential inducing effect of benzo[a]pyrene on gene expression and enzyme activity of cytochromes P450 1A1 and 1A2 in Sprague-Dawley and Wistar rats. Drug Metab. Pharmacokinet., <b>27<\/b>, 640-652.","DOI":"10.2133\/dmpk.DMPK-12-RG-035"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Guengerich, F.P. (2008): Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol., <b>21<\/b>, 70-83.","DOI":"10.1021\/tx700079z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Guengerich, F.P. (2015): Human Cytochrome P450 Enzymes. In: Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P.R., ed.), pp. 523-785, Springer International Publishing, Cham.","DOI":"10.1007\/978-3-319-12108-6_9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Jonker, J.W., Liddle, C. and Downes, M. (2012): FXR and PXR: potential therapeutic targets in cholestasis. J. Steroid Biochem. Mol. Biol., <b>130<\/b>, 147-158.","DOI":"10.1016\/j.jsbmb.2011.06.012"},{"key":"12","doi-asserted-by":"publisher","unstructured":"Kaito, S., Takeshita, J.I., Iwata, M., Sasaki, T., Hosaka, T., Shizu, R. and Yoshinari, K. (2024): Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury. Xenobiotica, <b>54<\/b>, 411-419.","DOI":"10.1080\/00498254.2024.2312505"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kliewer, S.A. and Willson, T.M. (2002): Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J. Lipid Res., <b>43<\/b>, 359-364.","DOI":"10.1016\/S0022-2275(20)30141-3"},{"key":"14","doi-asserted-by":"publisher","unstructured":"Klyushova, L.S., Perepechaeva, M.L. and Grishanova, A.Y. (2022): The Role of CYP3A in Health and Disease. Biomedicines, <b>10<\/b>, 2686.","DOI":"10.3390\/biomedicines10112686"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Lewis, D.F., Lake, B.G. and Dickins, M. (2007): Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity. J. Enzyme Inhib. Med. Chem., <b>22<\/b>, 1-6.","DOI":"10.1080\/14756360600952183"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Lu, J., Shang, X., Yao, B., Sun, D., Liu, J., Zhang, Y., Wang, H., Shi, J., Chen, H., Shi, T., Liu, M. and Wang, X. (2023): The role of CYP1A1\/2 in cholesterol ester accumulation provides a new perspective for the treatment of hypercholesterolemia. Acta Pharm. Sin. B, <b>13<\/b>, 648-661.","DOI":"10.1016\/j.apsb.2022.08.005"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Rendic, S.P. and Guengerich, F.P. (2024): Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes. Arch. Toxicol., <b>98<\/b>, 1581-1628.","DOI":"10.1007\/s00204-024-03710-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Sakuratani, Y., Zhang, H.Q., Nishikawa, S., Yamazaki, K., Yamada, T., Yamada, J., Gerova, K., Chankov, G., Mekenyan, O. and Hayashi, M. (2013): Hazard Evaluation Support System (HESS) for predicting repeated dose toxicity using toxicological categories. SAR QSAR Environ. Res., <b>24<\/b>, 351-363.","DOI":"10.1080\/1062936X.2013.773375"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Shibata, M., Uchida, N., Ooka, A., Shizu, R. and Yoshinari, K. (2025): Cytochrome P450 inhibition correlates with hepatotoxicity of pesticides: analysis using repeated-dose toxicity data in rats. Drug Metab. Pharmacokinet., in press.","DOI":"10.1016\/j.dmpk.2025.101505"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Shimizu, Y., Sasaki, T., Yonekawa, E., Yamazaki, H., Ogura, R., Watanabe, M., Hosaka, T., Shizu, R., Takeshita, J.I. and Yoshinari, K. (2021): Association of CYP1A1 and CYP1B1 inhibition in <i>in vitro<\/i> assays with drug-induced liver injury. J. Toxicol. Sci., <b>46<\/b>, 167-176.","DOI":"10.2131\/jts.46.167"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Sonkar, R., Ma, H. and Waxman, D.J. (2024): Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: primary and secondary gene responses with links to disease progression. Toxicol. Sci., <b>200<\/b>, 324-345.","DOI":"10.1093\/toxsci\/kfae057"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Sun, D., Lu, J., Zhang, Y., Liu, J., Liu, Z., Yao, B., Guo, Y. and Wang, X. (2021): Characterization of a Novel <i>CYP1A2<\/i> Knockout Rat Model Constructed by CRISPR\/Cas9. Drug Metab. Dispos., <b>49<\/b>, 638-647.","DOI":"10.1124\/dmd.121.000403"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Takeshita, J.I., Goto, Y., Yamamoto, S., Sasaki, T. and Yoshinari, K. (2024): Comprehensive analysis of the toxicity-related findings from repeated-dose subacute toxicity studies of industrial chemicals in male rats. Crit. Rev. Toxicol., <b>54<\/b>, 996-1010.","DOI":"10.1080\/10408444.2024.2427221"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Watanabe, M., Sasaki, T., Takeshita, J.I., Kushida, M., Shimizu, Y., Oki, H., Kitsunai, Y., Nakayama, H., Saruhashi, H., Ogura, R., Shizu, R., Hosaka, T. and Yoshinari, K. (2020): Application of cytochrome P450 reactivity on the characterization of chemical compounds and its association with repeated-dose toxicity. Toxicol. Appl. Pharmacol., <b>388<\/b>, 114854.","DOI":"10.1016\/j.taap.2019.114854"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Wincent, E., Amini, N., Luecke, S., Glatt, H., Bergman, J., Crescenzi, C., Rannug, A. and Rannug, U. (2009): The suggested physiologic aryl hydrocarbon receptor activator and cytochrome P4501 substrate 6-formylindolo[3,2-b]carbazole is present in humans. J. Biol. Chem., <b>284<\/b>, 2690-2696.","DOI":"10.1074\/jbc.M808321200"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Yamazoe, Y., Ito, K., Yamamura, Y., Iwama, R. and Yoshinari, K. (2016): Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 1. Focusing on polycyclic arenes and the related chemicals. Drug Metab. Pharmacokinet., <b>31<\/b>, 363-384.","DOI":"10.1016\/j.dmpk.2016.07.005"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Yamazoe, Y. and Yoshinari, K. (2017): Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: solving substrate interactions of CYP1A2 with non-PAH substrates on the template system. Drug Metab. Pharmacokinet., <b>32<\/b>, 229-247.","DOI":"10.1016\/j.dmpk.2017.05.004"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Yamazoe, Y. and Yoshinari, K. (2020): Prediction of regioselectivity and preferred order of CYP1A1-mediated metabolism: solving the interaction of human and rat CYP1A1 forms with ligands on the template system. Drug Metab. Pharmacokinet., <b>35<\/b>, 165-185.","DOI":"10.1016\/j.dmpk.2019.10.008"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Yoda, T., Tochitani, T., Usui, T., Kouchi, M., Inada, H., Hosaka, T., Kanno, Y., Miyawaki, I. and Yoshinari, K. (2022): Involvement of the CYP1A1 inhibition-mediated activation of aryl hydrocarbon receptor in drug-induced hepatotoxicity. J. Toxicol. Sci., <b>47<\/b>, 359-373.","DOI":"10.2131\/jts.47.359"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Yu, K., Geng, X., Chen, M., Zhang, J., Wang, B., Ilic, K. and Tong, W. (2014): High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab. Dispos., <b>42<\/b>, 744-750.","DOI":"10.1124\/dmd.113.056267"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Zeldin, D.C. (2001): Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem., <b>276<\/b>, 36059-36062.","DOI":"10.1074\/jbc.R100030200"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/5\/51_321\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:17:07Z","timestamp":1777695427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/5\/51_321\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.51.321","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}